Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 5, 2004, Pages 437-458

  Gopalakrishnan, Murali ^a   Shieh, Char Chang ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ATP sensitive K+ channels (KATP); Ca2+ activated K+ channels (KCa); Erectile dysfunction; Molecular targets; Overactive bladder; Potassium channel opener (KCO); Prostate cancer; Voltage dependent K+ channel KQT like subfamily (KCNQ) channels

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 (5 CHLORO 2 HYDROXYPHENYL) 5 TRIFLUOROMETHYL 2 BENZIMIDAZOLONE; 1 [4 (1H IMIDAZOL 1 YL)BENZOYL] N METHYLCYCLOBUTANECARBOTHIOAMIDE; 2 (3,4 DIHYDRO 2,2 DIMETHYL 6 NITRO 2H 1,4 BENZOXAZIN 4 YL)PYRIDINE 1 OXIDE; 2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; 3 (2,4 DICHLORO 6 METHYLBENZYLAMINO) 4 (1,1 DIMETHYLPROPYLAMINO) 3 CYCLOBUTENE 1,2 DIONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 [3,4 DIOXO 2 (1,2,2 TRIMETHYLPROPYLAMINO) 1 CYCLOBUTENYLAMINO] 3 ETHYLBENZONITRILE; A 151892; A 278637; A 308191; A 312110; A 411873; BMS 191011; CALCIUM ACTIVATED POTASSIUM CHANNEL; CGS 7181; CROMAKALIM; DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NIFEDIPINE; NS 1608; NS 8; OXYBUTYNIN; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL STIMULATING AGENT; SDZ 217 744; SOLIFENACIN; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; ZD 0947;

CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ERECTILE DYSFUNCTION; GENE EXPRESSION; HEADACHE; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR CLONING; NONHUMAN; OVERACTIVE BLADDER; PROSTATE DISEASE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RASH; REVIEW; TISSUE DISTRIBUTION; URINARY TRACT DISEASE;

AGED; ANIMALS; CALCIUM; DOUBLE-BLIND METHOD; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; HAPLORHINI; HUMANS; IMPOTENCE; ION TRANSPORT; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; PENILE ERECTION; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RATS; STIMULATION, CHEMICAL; SWINE; URINARY BLADDER DISEASES; URINARY BLADDER, NEUROGENIC; URINATION; URINATION DISORDERS;

EID: 4644244821     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.5.437     Document Type: Review

References (212)

1. MORELAND RB, BRIONI JD, SULLIVAN JP: Emerging pharmacology approaches for the treatment of lower urinary tract disorders. J. Pharmacol Exp. Ther. (2004) 308:797-804.
2. YOSHIMURA N, CHANCELLOR MB: Current and future pharmacological treatment for overactive bladder. J. Urol. (2002) 168:1897-1913.
3. MICHEL MC, BRIONI JD: Meeting report for the ASPET Ray Fuller symposium: lower uinary tract disorders: physiology, pharmacology, and therapeutic approaches. J. Pharmacol. Exp. Ther. (2002) 303:431-437.
4. PAPAZIAN DM, SCHWARZ TL, TEMPEL BL, JAN YN, JAN LY: Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science (1987) 237:749-753.
5. SHIEH CC, COGHLAN M, SULLIVAN JP, GOPALAKRISHNAN M: Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev. (2000) 52:557-594.
6. COGHLAN MJ, CARROLL WA, GOPALAKRISHNAN M: Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. (2001) 44:1627-1653.
7. BRADING AF: A myogenic basis for the overactive bladder. Urology (1997) 50:57-67; discussion 68-73.
8. HASHITANI H, FUKUTA H, TAKANO H, KLEMM MF, SUZUKI H: Origin and propagation of spontaneous excitation in smooth muscle of the guinea-pig urinary bladder. J. Physiol. (2001) 530:273-286.
9. KLOCKNER U, ISENBERG G: Action potentials and net membrane currents of isolated smooth muscle cells (urinary bladder of the guinea-pig). Pflugers Arch. (1985) 405:329-339.
10. GALLEGOS CR, FRY CH: Alterations to the electrophysiology of isolated human detrusor smooth muscle cells in bladder disease. J. Urol. (1994) 151:754-758.
11. + channels regulate action potential repolarization in urinary bladder smooth muscle. Am. J. Physiol. (1997) 273:C110-C117.
12. 2+ channels and ryanodine receptors in guinea-pig urinary bladder myocytes. J Physiol. (2002) 541:483-492.
13. + current. J. Physiol. (2003) 549:65-74.
14. HASHITANI H, BRADING AF: Ionic basis for the regulation of spontaneous excitation in detrusor smooth muscle cells of the guinea-pig urinary bladder. Br. J. Pharmacol. (2003) 140:159-169.
15. FUJII K, FOSTER CD, BRADING AF, PAREKH AB: Potassium channel blockers and the effects of cromakalim on the smooth muscle of the guinea-pig bladder. Br. J. Pharmacol. (1990) 99:779-785.
16. V α1 subunit expression and function in human detrusor muscle. J. Urol. (2002) 167:1881-1886.
17. + channel subtype transcripts in several types of smooth muscles of the rat. J. Smooth Muscle Res. (2000) 36:101-115.
18. 2+ transients and distribution of BK channels and ryanodine receptors in smooth muscle cells of guinea-pig vas deferens and urinary bladder. J. Physiol. (2001) 534:313-326.
19. + current during depolarization in smooth muscle cells of the guinea-pig vas deferens and urinary bladder. J. Physiol. (1998) 510:705-719.
20. HERRERA GM, HEPPNER TJ, NELSON MT: Regulation of urinary bladder smooth muscle contractions by ryanodine receptors and BK and SK channels. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279:R60-R68.
21. Ca channels in urinary bladder smooth muscle. Am. J. Physiol., Cell Physiol. (2001) 280:C481-C490.
22. MCMANUS OB, HELMS LM, PALLANCK L, GANETZKY B, SWANSON R, LEONARD RJ: Functional role of the β subunit of high conductance calcium-activated potassium channels. Neuron (1995) 14:645-650.
23. 2+-activated potassium channels by retaining the gating in the bursting states. J. Gen. Physiol. (1999) 113:425-440.
24. 2+ sensitivity. J. Gen. Physiol. (2000) 116:411-432.
25. + channel regulates contractile activity of mouse urinary bladder smooth muscle. J. Physiol. (2001) 537:443-452.
26. CHRIST GJ, DAY NS, SANTIZO C et al.: Bladder instillation of 'naked' hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Urology (2001) 57:111.
27. + channels in the pig and human detrusor. Eur. J. Pharmacol. (2000) 400:287-295.
28. HASHITANI H, BRADING AF: Electrical properties of detrusor smooth muscles from the pig and human urinary bladder. Br. J. Pharmacol. (2003) 140:146-158.
29. KOHLER M, HIRSCHBERG B, BOND CT et al.: Small-conductance, calcium-activated potassium channels from mammalian brain. Science (1996) 273:1709-1714.
30. HERRERA GM, POZO MJ, ZVARA P et al.: Urinary bladder instability induced by selective suppression of the murine small conductance calcium-activated potassium (SK3) channel. J. Physiol. (2003) 551:893-903.
31. ISHII TM, SILVIA C, HIRSCHBERG B, BOND CT, ADELMAN JP, MAYLIE J: A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Scz. USA (1997) 94:11651-11656.
32. + channels in mouse urinary bladder smooth muscle cells. Jpn. J. Pharmacol. (2000) 84:97-100.
33. + channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circ. Res. (1999) 85:e33-e43.
34. ATP channel complex. J. Gen. Physiol. (1997) 110:655-664.
35. + channel. J. Biol. Chem. (1996) 271:24321-24324.
36. + channel. J. Physiol. (1997) 499:715-720.
37. ATP) expressed in guinea pig bladder smooth muscle cells. J. Pharmacol. Exp. Ther. (1999) 289:551-558.
38. CHUTKOW WA, MAKIELSKI JC, NELSON DJ, BURANT CF, FAN Z: Alternative splicing of sur2 exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel. J. Biol. Chem. (1999) 274:13656-13665.
39. ATP channels. Gene (2000) 256:261-270.
40. ATP channels containing SUR2B splice variants expressed in L-cells. Eur. J. Pharmacol. (2004) 483:195-205.
41. DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50:36-52; discussion 53-56.
42. WEIN AJ: Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin. Investig. Drugs (2001) 10:65-83.
43. BLOK BF: Central pathways controlling micturition and urinary continence. Urology (2002) 59:13-17.
44. ANDERSSON KE: Bladder activation: afferent mechanisms. Urology (2002) 59:43-50.
45. ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21:167-178.
46. DE GROAT WC, NADELHAFT I, MILNE RJ, BOOTH AM, MORGAN C, THOR K: Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J. Auton. Nerv. Syst. (1981) 3:135-160.
47. HABLER HJ, JANIG W, KOLTZENBURG M: Receptive properties of myelinated primary afferents innervating the inflamed urinary bladder of the cat. J. Neurophysiol. (1993) 69:395-405.
48. HABLER HJ, JANIG W, KOLTZENBURG M: Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J. Physiol. (1990) 425:545-562.
49. MAZIERES L, JIANG C, LINDSTROM S: The C fibre reflex of the cat urinary bladder. J. Physiol. (1998) 513:531-541.
50. JIANG CH, MAZIERES L, LINDSTROM S: Cold- and menthol-sensitive C afferents of cat urinary bladder. J. Physiol. (2002) 543:211-220.
51. FOWLER CJ, JEWKES D, MCDONALD WI, LYNN B, DE GROAT WC: Intravesical capsaicin for neurogenic bladder dysfunction. Lancet (1992) 339:1239.
52. SILVA C, RIBEIRO MJ, CRUZ F: The effect of intravesical resiniferatoxin in patients with idiopathic dctrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J. Urol. (2002) 168:575-579.
53. IGAWA Y, SATOH T, MIZUSAWA H et al.: The role of capsaicin-sensitive afferents in autonomic dysreflexia in patients with spinal cord injury. BJU Int. (2003) 91:637-641.
54. LOWE EM, ANAND P, TERENGHI G, WILLIAMS-CHESTNUT RE, SINICROPI DV, OSBORNE JL: Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol. (1997) 79:572-577.
55. VIZZARD MA: Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp. Neurol. (2000) 161:273-284.
56. DUPONT MC, SPITSBERGEN JM, KIM KB, TUTTLE JB, STEERS WD: Histological and neurotrophic changes triggered by varying models of bladder inflammation. J. Urol. (2001) 166:1111-1118.
57. YOSHIMURA N, DE GROAT WC: Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J. Neurosci. (1999) 19:4644-4653.
58. DRAKE MJ, HEDLUND P, MILLS IW et al.: Structural and functional denervation of human detrusor after spinal cord injury. Lab. Invest. (2000) 80:1491-1499.
59. DRAKE MJ, GARDNER BP, BRADING AF: Innervation of the detrusor muscle bundle in neurogenic detrusor overactivity. BJU Int. (2003) 91:702-710.
60. SOMOGYI GT, ZERNOVA GV, YOSHIYAMA M, ROCHA JN, SMITH CP, DE GROAT WC: Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochem. Int. (2003) 43:73-77.
61. MILLS IW, GREENLAND JE, MCMURRAY G et al.: Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J. Urol. (2000) 163:646-651.
62. MILLS IW, NOBLE JG, BRADING AF: Radiotelemetered cystometry in pigs: validation and comparison of natural filling versus diuresis cystometry. J. Urol. (2000) 164:1745-1750.
63. + channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. Neurourol. Urodyn. (2003) 22:147-155.
64. HAEFLIGER JA, TISSIERES P, TAWADROS T et al.: Connexins 43 and 26 are differentially increased after rat bladder outlet obstruction. Exp. Cell Res. (2002) 274:216-225.
65. CHRIST GJ, DAY NS, DAY M et al.: Increased connexin43-mediated intercellular communication in a rat model of bladder overactiviry in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284:R1241-R1248.
66. SUI GP, COPPEN SR, DUPONT E et al.: Impedance measurements and connexin expression in human detrusor muscle from stable and unstable bladders. BJU Int. (2003) 92:297-305.
67. DISANTO ME, STEIN R, CHANG S et al.: Alteration in the expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am. J. Physiol. Cell Physiol. (2003) 30:30.
68. UVELIUS B, ARNER A: Changed metabolism of detrusor muscle cells from obstructed rat urinary bladder. Scand. J. Urol. Nephrol. Suppl. (1997) 184:59-65.
69. PARK JM, YANG T, AREND LJ, SMART AM, SCHNERMANN JB, BRIGGS JP: Cyclooxygenase-2 is expressed in bladder during fetal development and stimulated by outlet obstruction. Am. J. Physiol. (1997) 273:F538-F544.
70. QUAYLE JM, NELSON MT, STANDEN NB: ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. (1997) 77:1165-232.
71. BUCKNER SA, MILICIC I, DAZA AV, COGHLAN MJ, GOPALAKRISHNAN M: Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br. J. Pharmacol. (2002) 135:639-648.
72. LU SH, YAMAGATA T, ATSUKI K et al.: Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rat. Brain Res. (2002) 946:72-78.
73. SCULPTOREANU A, YOSHIMURA N, DE GROAT WC: KW-7158 enhances A-type K+ currents in neurons of the dorsal root ganglion of the adult rat. J. Pharmacol. Exp. Ther. (2004) 310(1):159-168.
74. NURSE DE, RESTORICK JM, MUNDY AR: The effect of cromakalim on the normal and hyper-reflexic human detrusor muscle. Br. J. Urol. (1991) 68:27-31.
75. KOMERSOVA K, ROGERSON JW, CONWAY EL et al.: The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions. Br. J. Clin. Pharmacol. (1995) 39:207-209.
76. HEDLUND H, MATTIASSON A, ANDERSSON KE: Effects of pinacidil on detrusor instability in men with bladder outlet obstruction. J. Urol. (1991) 146:1345-1347.
77. SUDOH K, MASUDA N, UCHIDA W: Different effect of anticholinergic agents and potassium channel openers on urinary bladder response to pelvic nerve stimulation in anaestherized dogs. J. Auton. Pharmacol. (1997) 17:91-96.
78. MASUDA N, UCHIDA W, SHIRAI Y, SHIBASAKI K, GOTO K, TAKENAKA T: Effect of the potassium channel opener YM934 on the contractile response to electrical field stimulation in pig detrusor smooth muscle. J. Urol. (1995) 154:1914-1920.
79. CHESS-WILLIAMS R, MARTIN SW, KORSTANJE C, CHAPPLE CR: In vitro investigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues. BJU Int. (1999) 83:1050-1054.
80. BURGGRAAF J, SCHOEMAKER RC, TERPSTRA IJ, COHEN AF: A Phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers. J. Clin. Pharmacol. (1998) 38:45-53.
81. ATP channel opener with in vivo selectivity for urinary bladder. J. Pharmacol. Exp. Ther. (1995) 274:884-890.
82. + channel opener, ZD6169, on volume and PGE2-stimulated bladder activity in conscious rats. J. Urol. (1997) 158:2300-2304.
83. + channel opener, ZD6169, in conscious rats with and without bladder outflow obstruction. J. Urol. (1999 162:943-948.
84. ATP channel opener, on bladder hyperactivity and spinal c-fos expression evoked by bladder irritation in rats. Brain Res. (1998) 807:11-18.
85. ATP channel opener, on neurally-mediated plasma extravasation in the rat urinary bladder induced by chemical or electrical stimulation of nerves. Brain Res. (2004) 996:41-46.
86. ATP channel opener, on the micturition reflex in the rat. J. Pharmacol. Exp. Ther. (1999) 290:825-831.
87. + channels by Zeneca ZD6169 in guinea pig bladder smooth muscle cells. J. Pharmacol. Exp. Ther. (1997) 280:38-45.
88. + channel opener ZD6169 on pig urethral smooth muscle. Br. J. Pharmacol. (2001) 134:1505-1515.
89. ABDEL-KARIM AM, BIALECKI RA, ELHILALI MM: Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J. Urol. (2002) 168:837-842.
90. WOJDAN A, FREEDEN C, WOODS M et al.: Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J. Pharmacol. Exp. Ther. (1999) 289:1410-1418.
91. LI JH, YASAY GD, KAU ST et al.: Studies of the K(ATP) channel opening activity of the new dihydropyridine compound 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridined ione in bladder detrusor in vitro. Arzneimittelforschung (1996) 46:525-530.
92. GOPALAKRISHNAN M, BUCKNER SA, WHITEAKER KL et al.: (-)-(9S)-9-(3-Bromo-4-fluorophenyl -2,3,5,6,7,9-hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. J. Pharmacol. Exp. Ther. (2002) 303:379-386.
93. BRUNE ME, FEY TA, BRIONI JD et al.: (-)-(9S)-9-(3-Bromo-4-fluorophenyl -2,3,5,6,7,9-hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. In vivo characterization. J. Pharmacol. Exp. Ther. (2002) 303:387-394.
94. GOPALAKRISHNAN M: Recent advances in potassium channel openers. ASPET-Ray Fuller Symposium New Drugs: Bench to Bedside: Diseases of Aging I. Symposium on 'Lower urinary tract disorders: Physiology, Pharmacology and Therapeutic Approaches, July 6 - 7 2002.
95. ATP channel openers. Bioorg. Med. Chem. Lett. (2003) 13:1741-1744.
96. + channel opener, A-151892. Br. J. Pharmacol. (2004) 143:81-90.
97. PEREZ-MEDRANO A, BUCKNER SA, COGHLAN MJ et al.: Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. Bioorg. Med Chem. Lett. (2004) 14:397-400.
98. + channel gene. J. Biol. Chem. (2000) 275:3991-3998.
99. BECKER MN, BRENNER R, ATKINSON NS: Tissue-specific expression of a Drosophila calcium-activated potassium channel. J. Neurosci. (1995) 15:6250-6259.
100. ZHANG XF, GOPALAKRISHNAN M, SHIEH CC: Modulation of action potential firing by iberiotoxin and NS1619 in rat dorsal root ganglion neurons. Neuroscience (2003) 122:1003-1011.
101. MCMANUS OB, HARRIS GH, GIANGIACOMO KM et al.: An activator of calcium-dependent potassium channels isolated from a medicinal herb. Biochemistry (1993) 32:6128-6133.
102. + channels by novel benzimidazolone. Eur. J. Pharmacol. (1994) 251:53-59.
103. + channels in cerebellar granule cells. Neuroreport (1994) 5:1001-1004.
104. 2+ release in smooth muscle cells of porcine coronary artery. Br. J. Pharmacol. (2001) 132:828-834.
105. KHAN RN, SMITH SK, ASHFORD ML, HUANG Y, LAU CW, HO IH: Contribution of calcium-sensitive potassium channels to NS1619-induced relaxation in human pregnant myometrium. Hum. Reprod. (1998) 13:208-213.
106. + currents in rat vas deferens. Eur. J. Pharmacol. (1997) 325:21-27.
107. Ca and inhibition of calcium currents. J. Pharmacol. Exp. Ther. (1997) 283:1193-200.
108. Ca channel activator, NS1619, on rat cerebral artery smooth muscle. Br. J. Pharmacol. (1996) 117:119-129.
109. Ca channel opener, in vascular smooth muscle. Br. J. Pharmacol. (1994) 113:1538-1547.
110. 2+. Neuropharmacology (1996) 35:903-914.
111. + channel α- and β-subunits in HEK293 cells. FEBS Lett. (1997) 415:67-70.
112. SIEMER C, BUSHFIELD M, NEWGREEN D, GRISSMER S: Effects of NS1608 on MaxiK channels in smooth muscle cells from urinary bladder. J. Membr. Biol. (2000) 173:57-66.
113. HU S, FINK CA, KIM HS, LAPPE RW: Novel and potent BK channel openers: CGS 7181 and its analogs. Drug Dev. Res. (1997) 41:10-21.
114. + channels and suppresses micturition reflex in rats. J. Urol. (1998) 159(Suppl.):21.
115. TANAKA M, SASAKI Y, KIMURA Y, FUKUI T, HAMADA K, UKAI Y: A novel pyrrole derivative, NS-8, suppresses the rat micturition reflex by inhibiting afferent pelvic nerve activity. BJU Int. (2003) 92:1031-1036.
116. HEWAWASAM P, ERWAY M, THALODY G et al.: The synthesis and structure-activity relationships of 1,3-diaryl 1,2,4-(4H)-triazol-5-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel opener targeted for urge urinary incontinence. Bioorg. Med. Chem. Lett. (2002) 12:1117-1120.
117. HEWAWASAM P, FAN W, DING M et al.: 4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction. J. Med. Chem. (2003) 46:2819-2822.
118. GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471-477.
119. 2+-dependent large-conductance potassium channels: symmetrical pharmacophore and electrophysiological evaluation of bisphenols. Bioorg. Med. Chem. Lett. (2003) 13:1437-1439.
120. SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P, STROBAEK D, JENSEN BS, OLESEN SP: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888-898.
121. DUPUIS DS, SCHRODER RL, JESPERSEN T et al.: Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur. J. Pharmacol. (2002) 437:129-137.
122. SCHRODER RL, STROBAEK D, OLESEN SP, CHRISTOPHERSEN P, JESPERSEN T, JENSEN BS: Voltage-independent KCNQ4 currents induced by (+/-)BMS-204352. Pflugers Arch. (2003) 446:607-616.
123. + channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles. Bioorg. Med. Chem. Lett. (2003) 13:2003-2007.
124. + channel openers in bladder and vascular smooth muscle. Naunyn Schmiedebergs Arch. Pharmacol. (2004).
125. JENTSCH TJ: Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev. Neurosci. (2000) 1:21-30.
126. COOPER EC, JAN LY: M-channels: neurological diseases, neuromodulation, and drug development. Arch. Neurol. (2003) 60:496-500.
127. GRIBKOFF VK: The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Ther. Targets (2003) 7:737-748.
128. SHLEDON JH, DAVIS A, NORTON NW et al.: Evidence of KCNQ gene expression and M-current activity in rat and human urinary bladder smooth muscle. In: The ASPET-Ray Fuller Symposium Series: Lower Urinary Tract Disorders: Physiology, pharmacology and therapeutic approches. San Francisco, USA (2002). Abstract.
129. MAIN MJ, CRYAN JE, DUPERE JR, COX B, CLARE JJ, BURBIDGE SA: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. (2000) 58:253-262.
130. TATULIAN L, DELMAS P, ABOGADIE FC, BROWN DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. (2001) 21:5535-5545.
131. WICKENDEN AD, YU W, ZOU A, JEGLA T, WAGONER PK: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. (2000) 58:591-600.
132. RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. (2000) 282:73-76.
133. WU YJ, DAVIS CD, DWORETZKY S et al.: Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: Identification of (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J. Med. Chem. (2003) 46:3778-3781.
134. WU YJ, BOISSARD CG, GRECO C et al.: (S)-N-[1-(3-Morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J. Med. Chem. (2003) 46:3197-3200.
135. GRONBERG H: Prostate cancer epidemiology. Lancet (2003) 361:859-864.
136. SMITH JR, FREIJE D, CARPTEN JD et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 274:1371-374.
137. COONEY KA, MCCARTHY JD, LANGE E et al.: Prostate cancer susceptibility locus on chromosome Iq: a confirmatory study. J. Nat. Cancer Inst. (1997) 89:955-959.
138. BERTHON P, VALERI A, COHEN-AKENINE A et al.: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am. J. Hum. Genet. (1998) 62:1416-1424.
139. XU J, MEYERS D, FREIJE D et al.: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. (1998) 20:175-179.
140. TAVTIGIAN SV, SIMARD J, TENG DH et al.: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. (2001) 27:172-180.
141. KORVER W, GUEVARA C, CHEN Y et al.: The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the γ-tubulin complex. Int. J. Cancer (2003) 104:283-288.
142. JANI AB, HELLMAN S: Early prostate cancer: clinical decision-making. Lancet (2003) 361:1045-1053.
143. MARTEL CL, GUMERLOCK PH, MEYERS FJ, LARA PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat. Rev. (2003) 29:171-187.
144. WILSON MJ, NORRIS H, WOODSON M, SINHA AA, ESTENSEN RD: Effects of aging and castration on plasminogen activator and metalloprotease activities in the rat prostate complex. Cell. Mol. Biol. Res. (1995) 41:603-612.
145. MIZOKAMI A, SAIGA H, MATSUI T, MITA T, SUGITA A: Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol. Jpn. (1992) 39:235-243.
146. LINDZEY J, GROSSMANN M, KUMAR MV, TINDALL DJ: Regulation of the 5′-flanking region of the mouse androgen receptor gene by CAMP and androgen. Mol. Endocrinol. (1993) 7:1530-1540.
147. CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563-566.
148. HSING AW, REICHARDT JK, STANCZYK FZ: Hormones and prostate cancer: current perspectives and future directions. Prostate (2002) 52:213-235.
149. HUDES GR: Signaling inhibitors in the treatment of prostate cancer. Invest. New Drugs (2002) 20:159-172.
150. WANG L, WHITLATCH LW, FLANAGAN JN, HOLICK MF, CHEN TC: Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res. (2003) 164:223-237.
151. SKRYMA RN, PREVARSKAYA NB, DUFY BARBE L, ODESSA MF, AUDIN J, DUFY B: Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate (1997) 33:112-122.
152. OUADID-AHIDOUCH H, VAN COPPENOLLE F, LE BOURHIS X, BELHAJ A, PREVARSKAYA N: Potassium channels in rat prostate epithelial cells. FEBS Lett. (1999) 459:15-21.
153. + channel activity in human prostate cancer cell lines of markedly different metastatic potential: distinguishing characteristics of PC-3 and LNCaP cells. Prostate (2001) 46:262-274.
154. + channel currents in rat ventral prostate epithelial cells. Prostate (2002) 51:201-210.
155. ABDUL M, HOOSEIN N: Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett. (2002) 186:99-105.
156. SMITH RD, GOLDIN AL: Functional analysis of the rat I sodium channel in xenopus oocytes. J. Neurosci. (1998) 18:811-820.
157. + current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer. J. Cell. Physiol. (1998) 175:50-58.
158. + channel α -subunit genes in rat and human prostate cancer cell lines. Prostate (2001) 48:165-178.
159. 2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line. J. Physiol. (1999) 517:95-107.
160. TSAVALER L, SHAPERO MH, MORKOWSKI S, LAUS R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. (2001) 61:3760-3769.
161. RAKE SG: The growth regulatory fibroblast IK channel is the prominent electrophysiological feature of rat prostatic cancer cells. Biochem. Biophys. Res. Commun. (2000) 269:457-463.
162. + channel modulators on human prostate cancer cell proliferation. Eur. J. Pharmacol. (2003) 471:157-164.
163. LOGSDON NJ, KANG J, TOGO JA, CHRISTIAN EP, AIYAR J: A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J. Biol. Chem. (1997) 272:32723-32726.
164. FRASER SP, GRIMES JA, DJAMGOZ MB: Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate (2000) 44:61-76.
165. RYBALCHENKO V, PREVARSKAYA N, VAN COPPENOLLE F et al.: Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Mol. Pharmacol. (2001) 59:1376-1387.
166. V1.3 switch in endogenous hippocampal microglia and a role in proliferation. J. Neurosci. (1999) 19:10680-10693.
167. Ca channel in human T
168. + channels. Proc Natl. Acad. Sci. USA (1999) 96:10917-10921.
169. Ca1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. (2000) 275:37137-37149.
170. 2+-ATPases 2B involvement in human prostate cancer cell growth control. J. Biol. Chem. (2001) 276:47608-47614.
171. SCHLICHTER L, SIDELL N, HAGIWARA S: Potassium channels mediate killing by human natural killer cells. Proc. Natl. Acad. Sci. USA (1986) 83:451-455.
172. Ca channels that hyperpolarize the membrane and enhance calcium influx. J. Gen. Physiol. (1999) 113:81-96.
173. FANGER CM, RAUER H, NEBEN AL et al.: Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J. Biol. Chem. (2001) 276:12249-12256.
174. BENZAQUEN LR, BRUGNARA C, BYERS HR, GATTON-CELLI S, HALPERIN JA: Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med. (1995) 1:534-540.
175. Ca1: a potential immunosuppressant. Proc. Natl. Acad. Sci. USA (2000) 97:8151-8156.
176. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA (2001) 98:13942-13947.
177. KOHLER R, WULFF H, EICHLER I et al.: Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 108:1119-1125.
178. STOCKER JW, DE FRANCESCHI L, MCNAUGHTON-SMITH GA, CORROCHER R, BEUZARD Y, BRUGNARA C: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood (2003) 101:2412-2418.
179. BIVALACQUA TJ, CHAMPION HC, HELLSTROM WJ, KADOWITZ PJ: Pharmacotherapy for erectile dysfunction. Trends Pharmacol. Sci. (2000) 21:484-489.
180. ANDERSSON KE: Pharmacology of penile erection. Pharmacol. Rev. (2001) 53:417-450.
181. NEHRA A, STEERS WD, ALTHOF SE et al.: Third international conference on the management of erectile dysfunction: linking pathophysiology and therapeutic response. J. Urol. (2003) 170:S3-S5.
182. ANDERSSON KE: Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J. Urol. (2003) 170:S6-S13.
183. FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. J. Clin. Epidemiol. (1994) 47:457-467.
184. MCKINLAY JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot. Res. (2000) 12:S6-S11.
185. MEULEMAN EJ: Prevalence of erectile dysfunction: need for treatment? Int. J. Impot. Res. (2002) 14:S22-S28.
186. SEFTEL AD: Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J. Urol. (2003) 169:1999-2007.
187. LAUMANN EO, PAIK A, ROSEN RC: The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int. J. Impot. Res. (1999) 11:S60-S64.
188. LIN CS, HO HC, GHOLAMI S, CHEN KC, JAD A, LUE TF: Gene expression profiling of an arteriogenic impotence model. Biochem. Biophys. Res. Commun. (2001) 285:565-569.
189. USER HM, ZELNER DJ, MCKENNA KE, MCVARY KT: Microarray analysis and description of SMR1 gene in rat penis in a post-radical prostatectomy model of erectile dysfunction. J. Urol. (2003) 170:298-301.
190. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. (2003) 83:1325-1358.
191. CHITALEY K, WINGARD CJ, CLINTON WEBB R et al.: Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. (2001) 7:119-122.
192. HAAS CA, SEFTEL AD, RAZMJOUEI K, GANZ MB, HAMPEL N, FERGUSON K: Erectile dysfunction in aging: upregulation of endothelial nitric oxide synthase. Urology (1998) 51:516-522.
193. FERRINI M, MAGEE TR, VERNET D, RAJFER J, GONZALEZ-CADAVID NF: Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol. Reprod. (2001) 64:974-982.
194. CHRIST GJ, SPRAY DC, BRINK PR: Characterization of K currents in cultured human corporal smooth muscle cells. J. Androl. (1993) 14:319-328.
195. Ca) channel in cultured human corporal smooth muscle cells. J. Urol. (1995) 153:818-825.
196. MALYSZ J, GIBBONS SJ, MILLER SM et al.: Potassium outward currents in freshly dissociated rabbit corpus cavernosum myocytes. J. Urol. (2001) 166:1167-1177.
197. + currents in myocytes from rabbit corpus cavernosum. J. Androl. (2002) 23:899-910.
198. ARCHER SL: Potassium channels and erectile dysfunction. Vascul. Pharmacol. (2002) 38:61-71.
199. +-channel openers for relaxation of isolated penile erectile tissue from rabbit. J. Urol. (1990) 144:146-151.
200. HEDLUND P, HOLMQUIST F, HEDLUND H, ANDERSSON KE: Effects of nicorandil on human isolated corpus cavernosum and cavernous artery. J. Urol. (1994) 151:1107-1113.
201. VENKATESWARLU K, GIRALDI A, ZHAO W et al.: Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J. Urol. (2002) 168:355-361.
202. ATP channel in human corporal smooth muscle cells. Int. J. Impot. Res. (2003) 15:258-266.
203. TRIGO-ROCHA F, DONATUCCI CF, HSU GL, NUNES L, LUE TF, TANAGHO EA: The effect of intracavernous injection of potassium channel openers in monkeys and dogs. Int. J. Impot. Res. (1995) 7:41-48.
204. ATP-channel opener as a potential treatment modality for erectile dysfunction. BJU Int. (1999) 83:837-841.
205. CAVALLINI G: Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J. Urol. (1991) 146:50-53.
206. RADOMSKI SB, HERSCHORN S, RANGASWAMY S: Topical minoxidil in the treatment of male erectile dysfunction. J. Urol. (1994) 151:1225-1226.
207. VICK RN, BENEVIDES M, PATEL M, PARIVAR K, LINNET O, CARSON CC: The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. J. Urol. (2002) 167:2618-2623.
208. 2+-activated potassium channels in smooth muscle cells of the human corpus cavernosum. Urol. Res. (2001) 29:359-365.
209. SPEKTOR M, RODRIGUEZ R, ROSENBAUM RS, WANG HZ, MELMAN A, CHRIST GJ: Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J. Urol. (2002) 167:2628-2635.
210. MELMAN A, ZHAO W, DAVIES KP, BAKAL R, CHRIST GJ: The successful long-term treatment of age-related erectile dysfunction with hSlo cDNA in rats in vivo. J. Urol. (2003) 170:285-290.
211. LU S-H, YAMAGATA T, ATSUKI K et al.: Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats. Brain Res. (2002) 946:72-78.
212. GUTMAN GA, CHANDY KG, ADELMAN JP et al.: International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol. Rev. (2003) 55:583-586.